

Electronic Acknowledgement Receipt

EFS ID:	6257967
Application Number:	10586023
International Application Number:	
Confirmation Number:	1717
Title of Invention:	Tricyclic benzazepine derivatives and their use
First Named Inventor/Applicant Name:	Elisabeth Woltering
Customer Number:	35969
Filer:	Gabriel J McCool
Filer Authorized By:	
Attorney Docket Number:	BHC 031067
Receipt Date:	16-OCT-2009
Filing Date:	17-FEB-2009
Time Stamp:	23:46:39
Application Type:	U.S. National Stage under 35 USC 371

Payment information:

Submitted with Payment	no
------------------------	----

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Foreign Reference	05-BHC031067-REF-BA-JP1993345785.pdf	1454202 292a430d7a349aaae695ad92728aebca7550a5e	no	25

Warnings:

Information:

2	Foreign Reference	06-BHC031067-REF-BB-EP875247.pdf	95388	no	15
			e9ee5769bb092351c997dc1388327279a0ee65f75		
Warnings:					
Information:					
3	Foreign Reference	07-BHC031067-REF-BC-EP638560.pdf	5570831	no	129
			0e3c736c05ac6f7821f2c023926e55eae0ebc590		
Warnings:					
Information:					
4	NPL Documents	08-BHC031067-REF-CA-Assmann-TheMunsterHeartStudy-PROCAM.PDF	710112	no	10
			d0688729f15b712c28ee12624d4210c1f025bda8		
Warnings:					
The page size in the PDF is too large. The pages should be 8.5 x 11 or A4. If this PDF is submitted, the pages will be resized upon entry into the Image File Wrapper and may affect subsequent processing					
Information:					
5	NPL Documents	09-BHC031067-REF-CB-Watson-7SqualeneSynthaselnhibitors.PDF	1812232	no	48
			bdfef0c165b60bb5db2c1c482d78902b99a0fe3d		
Warnings:					
Information:					
6	NPL Documents	10-BHC031067-REF-CC-Hiyoshi-SqualeneSynthaselnhibitorsReducePlasmaTriglyceride.pdf	751660	no	8
			a7bfa086bd5e2b5c5e4118949c6ec3c083302d33		
Warnings:					
Information:					
7	NPL Documents	11-BHC031067-REF-CD-Jian-SynthesisandBiologicalEvaluationof2-Styrylquinazolin.pdf	860575	no	8
			9314b2452529a4c642a5da6fe92581b13a3cc165		
Warnings:					
Information:					
8	NPL Documents	12-BHC031067-REF-CE-Miki-SynthesisofNovel4-1BenzoxazepineDerivatives.pdf	1286257	no	10
			305f7f70cca5c75e7ef262abc096d191e4cbd052		
Warnings:					
Information:					
9	NPL Documents	13-BHC031067-REF-CF-Papa-B-AroylacrylicAcids.pdf	628578	no	5
			1445141dcc8718f07923d88db9700f8097fc02df		
Warnings:					
Information:					
10	NPL Documents	14-BHC031067-REF-CG-Miki-Novel41-BenzoxazepineDerivatives.pdf	1298822	no	14
			3329939a27ccb2f3f80cd3446724bb65dde99898		

Warnings:					
Information:					
11	NPL Documents	15-BHC031067-REF-CH-Ma-TotalSynthesisof2S2S4R-PlakoridineA.pdf	205386	no	4
			c9ba4c5ab65bbd8b4aa19a1ed4b1823d0cac6dff		
Warnings:					
Information:					
12	NPL Documents	16-BHC031067-REF-CI-Weber-Bistriazolooxazepineunder-thiazepine.pdf	336473	no	7
			1825e908b7c45a99f71f951b774d5236ff319347		
Warnings:					
The page size in the PDF is too large. The pages should be 8.5 x 11 or A4. If this PDF is submitted, the pages will be resized upon entry into the Image File Wrapper and may affect subsequent processing					
Information:					
13	NPL Documents	17-BHC031067-REF-CJ-Duncan-DeterminationofFreeTotalandEsterified.pdf	864998	no	12
			1e82183a9080d5c4c8126c0da4d6367aaefaff4		
Warnings:					
Information:					
14	NPL Documents	18-BHC031067-REF-CK-Bischoff-Cerivastatin-PharmacologyofaNovelSynthetic.pdf	1198746	no	12
			9d130a326f3ae31c0dffded0b5d094c115ef2212		
Warnings:					
Information:					
15	Miscellaneous Incoming Letter	01-BHC031067-certEfile.pdf	13735	no	1
			2276a68cd8df9eb413119c637b85406b066bcd5b		
Warnings:					
Information:					
16	Miscellaneous Incoming Letter	02-BHC031067-Transmittal.pdf	28823	no	1
			86068c8695d0e34c93d9d423214d9cf9c40aa843		
Warnings:					
Information:					
17	Transmittal Letter	03-IDSLtr.pdf	20926	no	2
			1805b3eb7bbadcc6ce586ec933ff4183fcd3f465		
Warnings:					
Information:					
18	Information Disclosure Statement (IDS) Filed (SB/08)	04-IDSbyApplicant.pdf	54897	no	3
			f7535c1dd87a7d5344dc08ff1f5f248900cd8344d		
Warnings:					
Information:					

Total Files Size (in bytes):

17192641

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.